ETF Managers Group’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

ETF Managers Group’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,587	Closed	-$21K	–	864
2022 Q1	$21K	Buy	14,587 +51	+0.4%	+$83	﹤0.01%	686
2021 Q4	$38K	Sell	14,536 -2,636	-15%	-$7.97K	﹤0.01%	673
2021 Q3	$54K	Buy	17,172 +2,993	+21%	+$9.99K	﹤0.01%	654
2021 Q2	$52K	Buy	14,179 +5,184	+58%	+$17.3K	﹤0.01%	635
2021 Q1	$29K	Sell	8,995 -5,288	-37%	-$21.5K	﹤0.01%	657
2020 Q4	$50K	Sell	14,283 -2,151	-13%	-$7.7K	﹤0.01%	612
2020 Q3	$57K	Buy	16,434 +7,779	+90%	+$31.3K	﹤0.01%	610
2020 Q2	$40K	Buy	+8,655	New	+$38.3K	﹤0.01%	593

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

ETF Managers Group's PHAS Position: Q2 2022 in Review

ETF Managers Group sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2022, closing a stake of 14,587 shares — an estimated $21K sold.

ETF Managers Group first reported a position in PHAS in Q2 2020 and held it in 8 quarters. The position peaked at $57K in Q3 2020. 49 funds tracked by Wall St. Rank hold PHAS as of Q2 2022.

ETF Managers Group reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
ETF Managers Group sold 14,587 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $21K.
ETF Managers Group first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
ETF Managers Group's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $57K in Q3 2020.
49 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on ETF Managers Group's 13F filing for Q2 2022, filed 15 Aug 2022.